FDA OKs Romosozumab for Postmenopausal Osteoporosis FDA OKs Romosozumab for Postmenopausal Osteoporosis

Romosozumab should be reserved for women at high risk for fracture who fail other therapies and should be avoided in women with a history of heart attack or stroke.FDA Approvals
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Diabetes & Endocrinology News Alert Source Type: news